Galectin Therapeutics Inc. (GALT): רווח נקי למניה ב-12 החודשים האחרונים

Galectin Therapeutics (GALT) relies on a closed cirrhosis therapy system, creating high barriers to entry for competitors. The annual net income per share trend confirms this stability, with -0.43 representing the current metric value. A focus on advanced stages of fibrosis ensures long-term patent monetization, although late-stage trials temporarily increase capital expenditures due to the absence of revenue.

Galectin Therapeutics pharmaceutical operations are exposed to risks of supply chain disruptions from Asia and patent disputes affecting development costs. By analyzing the TTM net income per share, an investor assesses the real equity value of the business over a year excluding dilution, which allows for the distinction between sustainable capitalization growth and short-term market volatility.